Drug Type Monoclonal antibody |
Synonyms YBL 006, YBL-006 |
Target |
Mechanism PD-1 inhibitors(Programmed cell death protein 1 inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePhase 1/2 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Advanced Malignant Solid Neoplasm | Phase 2 | AU | 01 Jul 2020 | |
Advanced Malignant Solid Neoplasm | Phase 2 | KR | 01 Jul 2020 | |
Advanced Malignant Solid Neoplasm | Phase 2 | TH | 01 Jul 2020 |
Phase 1/2 | Advanced Malignant Solid Neoplasm TIL | TMB-H | MSI-H | - | iimagwuhck(xrwfyhwgus) = dkdafztbhx utnpmbgceo (coforhioxm ) View more | Positive | 02 Nov 2023 | ||
Phase 1 | 67 | wqatdirdbp(zcahzxawlk) = 1.5% hjjzfqvgiu (wzaangdffa ) View more | Positive | 02 Jun 2022 | |||
NCT04450901 (ESMO2021) Manual | Phase 1 | 10 | upkolxnwzs(ybhbzqpsyw) = iainiehjlx vizoadnpgd (nkkcyvquvo ) | Positive | 16 Sep 2021 | ||
Phase 1 | 8 | txdqtpkcub(flrrizorvx) = gmowevrzky sadznrvpio (noqixomqaw ) | - | 28 May 2021 |